Stocksigma LogoStocksigma Logo

Fredun Pharmaceuticals Delivers Strong H1 FY27 Growth with Strategic Pet-Care Expansion

Fredun Pharmaceuticals reported robust standalone financial results for H1 FY27, with total income rising 87.02% YoY to ₹495.88 Cr

Fredun Pharmaceuticals Delivers Strong H1 FY27 Growth with Strategic Pet-Care Expansion

Fredun Pharmaceuticals Ltd · Press Release · 06 Nov 2026, 2:32 pm

Fredun Pharmaceuticals Delivers Strong H1 FY27 Growth with Strategic Pet-Care Expansion Fredun Pharmaceuticals reported robust standalone financial results for H1 FY27, with total income rising 87.02% YoY to ₹495.88 Cr. EBITDA surged 91.67% YoY to ₹75.38 Cr as EBITDA margins expanded 37 bps to 15.20%, while net profit rose 93.92% YoY to ₹31.99 Cr. For Q2 FY27, total income grew 84.21% YoY to ₹267.64 Cr and net profit rose 93.44% YoY to ₹18.83 Cr. Strategically, Fredun expanded its pet-wellness ecosystem in Sep'26 by acquiring Furlicks and securing a 26% stake in Goodman Vetcare at a ₹300 Cr valuation.

Original exchange filing (PDF)

More announcements from Fredun Pharmaceuticals Ltd

All Fredun Pharmaceuticals Ltd announcements